Literature DB >> 25120338

Efficacy of intravitreal anti-vascular endothelial growth factor or steroid injection in diabetic macular edema according to fluid turbidity in optical coherence tomography.

Kyungmin Lee1, Heeyoung Chung1, Youngsuk Park1, Joonhong Sohn1.   

Abstract

PURPOSE: To determine if short term effects of intravitreal anti-vascular endothelial growth factor or steroid injection are correlated with fluid turbidity, as detected by spectral domain optical coherence tomography (SD-OCT) in diabetic macular edema (DME) patients.
METHODS: A total of 583 medical records were reviewed and 104 cases were enrolled. Sixty eyes received a single intravitreal bevacizumab injection (IVB) on the first attack of DME and 44 eyes received triamcinolone acetonide treatment (IVTA). Intraretinal fluid turbidity in DME patients was estimated with initial intravitreal SD-OCT and analyzed with color histograms from a Photoshop program. Central macular thickness and visual acuity using a logarithm from the minimum angle of resolution chart, were assessed at the initial period and 2 months after injections.
RESULTS: Visual acuity and central macular thickness improved after injections in both groups. In the IVB group, visual acuity and central macular thickness changed less as the intraretinal fluid became more turbid. In the IVTA group, visual acuity underwent less change while central macular thickness had a greater reduction (r = -0.675, p = 0.001) as the intraretinal fluid was more turbid.
CONCLUSIONS: IVB and IVTA injections were effective in reducing central macular thickness and improving visual acuity in DME patients. Further, fluid turbidity, which was detected by SD-OCT may be one of the indexes that highlight the influence of the steroid-dependent pathogenetic mechanism.

Entities:  

Keywords:  Bevacizumab; Diabetic macular edema; Intravitreal triamcinolone acetonide injection; Optical coherence tomography; Turbidity

Mesh:

Substances:

Year:  2014        PMID: 25120338      PMCID: PMC4120350          DOI: 10.3341/kjo.2014.28.4.298

Source DB:  PubMed          Journal:  Korean J Ophthalmol        ISSN: 1011-8942


  23 in total

1.  Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.

Authors:  Ji Won Lim; Hyo Kyoung Lee; Min Cheol Shin
Journal:  Ophthalmologica       Date:  2011-10-12       Impact factor: 3.250

2.  Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema.

Authors:  J A Montero; J M Ruiz-Moreno; C De La Vega
Journal:  Eur J Ophthalmol       Date:  2008 May-Jun       Impact factor: 2.597

3.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

4.  Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.

Authors:  Hee Jin Sohn; Dae Heon Han; Im Tae Kim; In Kyung Oh; Kyun Hyung Kim; Dae Yeong Lee; Dong Heun Nam
Journal:  Am J Ophthalmol       Date:  2011-07-22       Impact factor: 5.258

5.  Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment.

Authors:  Pei-Chen Wu; Chien-Hsiung Lai; Ching-Lung Chen; Chien-Neng Kuo
Journal:  J Ocul Pharmacol Ther       Date:  2011-10-12       Impact factor: 2.671

6.  Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables.

Authors:  David J Browning; Rajendra S Apte; Susan B Bressler; Kakarla V Chalam; Ronald P Danis; Matthew D Davis; Craig Kollman; Haijing Qin; Srinivas Sadda; Ingrid U Scott
Journal:  Retina       Date:  2009-03       Impact factor: 4.256

7.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2009-08-22       Impact factor: 12.079

8.  Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.

Authors:  Hamid Ahmadieh; Alireza Ramezani; Nasser Shoeibi; Bijan Bijanzadeh; Ali Tabatabaei; Mohsen Azarmina; Masoud Soheilian; Gholamreza Keshavarzi; Mohammad-Reza Mohebbi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-05       Impact factor: 3.117

9.  Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

Authors:  L Paccola; R A Costa; M S Folgosa; J C Barbosa; I U Scott; R Jorge
Journal:  Br J Ophthalmol       Date:  2007-10-26       Impact factor: 4.638

10.  Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.

Authors:  Masoud Soheilian; Alireza Ramezani; Arash Obudi; Bijan Bijanzadeh; Masoud Salehipour; Mehdi Yaseri; Hamid Ahmadieh; Mohammad H Dehghan; Mohsen Azarmina; Siamak Moradian; Gholam A Peyman
Journal:  Ophthalmology       Date:  2009-04-19       Impact factor: 12.079

View more
  4 in total

1.  Intracystic hyperreflective material in centre-involving diabetic macular oedema.

Authors:  Ramesh Venkatesh; Sajjan Sangai; Nikitha Gurram Reddy; Akhila Sridharan; Arpitha Pereira; Aditya Aseem; Santosh Gopi Krishna Gadde; Naresh Kumar Yadav; Jay Chhablani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-12       Impact factor: 3.117

2.  Diabetic Retinopathy and Diabetic Macular Edema in People With Early-Onset Diabetes.

Authors:  Nikitha Gurram Reddy; Ramesh Venkatesh; Chaitra Jayadev; Santosh Gopi Krishna Gadde; Sameeksha Agrawal; Pranjal Mishra; Naresh Kumar Yadav; Jay Chhablani
Journal:  Clin Diabetes       Date:  2022-04-15

Review 3.  The Vitreomacular Interface in Diabetic Retinopathy.

Authors:  Daniel Agarwal; Rachel Gelman; Claudia Prospero Ponce; William Stevenson; John B Christoforidis
Journal:  J Ophthalmol       Date:  2015-09-03       Impact factor: 1.909

4.  Clinical Implications of Suspended Scattering Particles in Motion Observed by Optical Coherence Tomography Angiography.

Authors:  Jaemoon Ahn; Sangheon Han; So Min Ahn; Seong-Woo Kim; Jaeryung Oh
Journal:  Sci Rep       Date:  2020-01-08       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.